Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
Amtagvi’s approval introduces a novel approach in the treatment of advanced melanoma, employing patient-derived TIL-cell therapy to target tumors with precision, offering a beacon of hope for those with limited options.
Dermatology March 4th 2024
Medical Professionals Reference (MPR)
Explore groundbreaking therapies in the pipeline: Onivyde for pancreatic cancer, showing marked survival benefits, and roluperidone, offering new hope in managing schizophrenia’s negative symptoms.
Hematology/Oncology January 22nd 2024
The New England Journal of Medicine
A look into the complexities of managing advanced melanoma with BRAF–MEK inhibitors, highlighting a case study where treatment-induced toxic effects posed significant diagnostic and therapeutic challenges.
Cancer Therapy Advisor
Discover how pre-surgery treatment with T-VEC can significantly improve long-term survival rates in advanced melanoma patients, as revealed in a recent phase 2 trial.
Dermatology October 2nd 2023
Clinical Advances in Hematology & Oncology
Explore the intricacies of diagnosing and treating acral melanoma, a subtype that presents unique challenges but also offers new avenues for targeted therapies and immune modulation.
Oncology, Medical August 28th 2023
Explore the latest research from McGill University that uncovers the demographic factors influencing melanoma risk, offering actionable insights for targeted prevention strategies.
Dermatology August 28th 2023